Navigation Links
Kosan's Lead Hsp90 Inhibitor, Tanespimycin, Shows High Level of Activity in Trastuzumab Resistant/Refractory HER2-Positive Breast Cancer in a Phase 2 Trial
Date:6/3/2008

risk factors are discussed under "Risk Factors" in Kosan's Annual Report on Form 10-K for the year ended December 31, 2007 and other periodic filings with the SEC. Kosan expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein.

Velcade(R) (bortezomib) is a registered trademark of Millennium Pharmaceuticals, Inc.

Herceptin(R) (trastuzumab) is a registered trademark of Genentech, Inc.

Cremophor(R) is a registered trademark of BASF Corporation


'/>"/>
SOURCE Kosan Biosciences Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. NexGenix Pharmaceuticals Presents Data on a Novel Small Molecule Inhibitor of Heat Shock Protein 90 (Hsp90) at the GTCbio Cancer Drugs Research & Development Conference
2. Kosan Initiates Phase 2 Trial of Alvespimycin, Second-Generation Hsp90 Inhibitor, in HER2-Positive Metastatic Breast Cancer
3. Kosan Presents Updated Data on Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma at Ash
4. First High-Res 3-D Structures of Mammalian HSP90 Protein Solved, Key to Better Targets for AIDS, Sepsis, Cancer Drugs
5. Kosans Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial
6. Kosan Opens Registration Program for Lead Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma
7. BiPar Sciences Expands Clinical Development of BSI-201, A Novel PARP Inhibitor, With Phase 2 Trial in Uterine Cancer
8. BiPar Sciences Announces Clinical Data Presentations on Lead PARP Inhibitor, BSI-201, at 40th American Society of Clinical Oncology Annual Meeting
9. BiPar Sciences Expands Phase 2 Clinical Trials of BSI-201, a Novel DNA Repair Inhibitor, in Ovarian Cancer
10. SuperGen Identifies Lead PIM Kinase Inhibitor, SGI-1776, That Causes Tumor Regression in AML Xenograft Models
11. SuperGens DNA Methyltransferase Inhibitor, S-110, Improves In Vivo Efficacy Profile of Decitabine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... , Sept. 30, 2014 /PRNewswire/ ... CHDX ) today announced the completion of ... for $24.00 per share in cash.  Healthy Harmony is ... Ltd. ("Fosun") and Ms. Roberta Lipson , the ... merger agreement was adopted by Chindex,s stockholders at a ...
(Date:9/30/2014)... Calif. , Sept. 30, 2014  Allakos ... additional $10 million investment from current investors to ... additional financing was completed following achievement of a ... antibody program, and represents an extension of the ... in December 2012. With this additional financing, Allakos ...
(Date:9/29/2014)... SAN DIEGO , 29 septembre 2014 /PRNewswire/ ... Sankyo) (TSE : 4568) et Ambit Biosciences (NASDAQ : AMBI), ... de fusion définitif en vertu duquel Daiichi Sankyo ... en circulation d,Ambit Biosciences à 15 dollars par ... publique d,achat qui sera suivie d,une fusion avec ...
Breaking Medicine Technology:Chindex Completes Go-Private Transaction With Healthy Harmony Holdings, L.P. 2Chindex Completes Go-Private Transaction With Healthy Harmony Holdings, L.P. 3Chindex Completes Go-Private Transaction With Healthy Harmony Holdings, L.P. 4Chindex Completes Go-Private Transaction With Healthy Harmony Holdings, L.P. 5Allakos Inc. Raises Additional $10 Million to Expand its Portfolio and Fund Development of an Additional Antibody for Allergic and Inflammatory Diseases 2Allakos Inc. Raises Additional $10 Million to Expand its Portfolio and Fund Development of an Additional Antibody for Allergic and Inflammatory Diseases 3Allakos Inc. Raises Additional $10 Million to Expand its Portfolio and Fund Development of an Additional Antibody for Allergic and Inflammatory Diseases 4Daiichi Sankyo va acquérir Ambit Biosciences 2Daiichi Sankyo va acquérir Ambit Biosciences 3Daiichi Sankyo va acquérir Ambit Biosciences 4Daiichi Sankyo va acquérir Ambit Biosciences 5Daiichi Sankyo va acquérir Ambit Biosciences 6Daiichi Sankyo va acquérir Ambit Biosciences 7Daiichi Sankyo va acquérir Ambit Biosciences 8Daiichi Sankyo va acquérir Ambit Biosciences 9
... OMAHA, Neb., May 15 Creighton Medical Laboratories, based ... Omaha, announced today that it has become the first ... effective testing method for cancer. The method, called SNP ... laboratories to study cancer for several years. However, Creighton ...
... , in Damaged Tissue and Cells MANDEVILLE, La., ... leading expert in the field of non-surgical skin rejuvenation ... to speed up the healing process of damaged tissue ... a double-blinded, placebo-controlled clinical study of a glycerin-based bruise-reaction ...
Cached Medicine Technology:Creighton Medical Laboratories First to Offer New Cancer Test 2Creighton Medical Laboratories First to Offer New Cancer Test 3Glycerin Proven to Improve Bruising and Swelling Caused By Trauma to Skin 2
(Date:9/30/2014)... HealthDay Reporter MONDAY, ... should be the first choice of birth control for ... Pediatrics state. Although most U.S. teens opt for ... contraception -- intrauterine devices (IUDs) and contraceptive implants -- ... And they should be the "first-line" choices for teenage ...
(Date:9/30/2014)... Houstonians seeking the latest information about ... on the Internet. Paul Vitenas, JR. M.D., F.A.C.S., ... surgeons, has launched a new website to better inform ... Botox Cosmetic services. The new website can be ... the new website, Botox Cosmetic is a non-surgical injectable ...
(Date:9/30/2014)... (PRWEB) September 30, 2014 ... caring individuals, National Children’s Oral Health Foundation: ... in grants to non-profit clinical partners. These ... Network and deliver comprehensive educational, preventive and ... Recipients include:,     Just Kids ...
(Date:9/30/2014)... TUESDAY, Sept. 30, 2014 (HealthDay News) -- For millions ... against excess weight and the threat of type 2 ... battle may be tougher for some than for others, ... promotes good health, it may not be as effective ... type 2 diabetes," said one expert, Dr. Ruth Loos, ...
(Date:9/30/2014)... 30, 2014 The global market for ... 38.75 billion by 2020 at an estimated CAGR of ... study by Grand View Research, Inc. Increasing prevalence of ... habits such as excessive alcohol consumption and growing geriatric ... is expected to serve this market as a high ...
Breaking Medicine News(10 mins):Health News:Pediatricians Endorse IUDs, Implants for Teen Birth Control 2Health News:Pediatricians Endorse IUDs, Implants for Teen Birth Control 3Health News:Dr. Paul Vitenas Launches New Website To Showcase The Benefits Of Botox Cosmetic 2Health News:Dr. Paul Vitenas Launches New Website To Showcase The Benefits Of Botox Cosmetic 3Health News:America's ToothFairy Awards More Than $150,000 in Grants to Save Young Smiles 2Health News:America's ToothFairy Awards More Than $150,000 in Grants to Save Young Smiles 3Health News:Can Exercise Prevent Type 2 Diabetes? Your Genes May Be Key 2Health News:Global Artificial Organ & Bionics Market Is Expecting Growth At CAGR Of 40.0% In Brain Bionics Segment From 2014 To 2020: Grand View Research, Inc. 2Health News:Global Artificial Organ & Bionics Market Is Expecting Growth At CAGR Of 40.0% In Brain Bionics Segment From 2014 To 2020: Grand View Research, Inc. 3Health News:Global Artificial Organ & Bionics Market Is Expecting Growth At CAGR Of 40.0% In Brain Bionics Segment From 2014 To 2020: Grand View Research, Inc. 4Health News:Global Artificial Organ & Bionics Market Is Expecting Growth At CAGR Of 40.0% In Brain Bionics Segment From 2014 To 2020: Grand View Research, Inc. 5Health News:Global Artificial Organ & Bionics Market Is Expecting Growth At CAGR Of 40.0% In Brain Bionics Segment From 2014 To 2020: Grand View Research, Inc. 6
... the largest,provider of business services to orthodontic and ... Texas and Atlanta, Georgia to,better serve the company,s ... offices confirm our operating principle that the,heart of ... but in the,hundreds of practices we serve each ...
... INDIANAPOLIS Public health officials are constantly in ... a possible pandemic, but to fight these deadly ... need it faster. , Researchers from the Regenstrief ... have found that automated electronic medical laboratory reporting ...
... TALLAHASSEE, Fla. -- About 5,000 people around the world die ... been developed to combat it in 40 years. Researchers at ... hope to change that through research made possible by a ... award will make it possible for Timothy A. Cross, the ...
... their relatives wish to donate organs when they die, because ... protecting the body of the deceased, according to research in ... University of Southampton, UK, spoke to 26 people who had ... organ donations about their views and experiences. The 23 relatives ...
... China, Jan. 17 /Xinhua-PRNewswire-FirstCall/ -- China Nepstar,Chain ... Nepstar" or "the Company"), the,largest drugstore chain ... join the,Shenzhen Charity Federation to launch a ... health issues among low-income working women,residents in ...
... industry,s voluntary withdrawal of oral ... and cold medicines in October 2007, WASHINGTON, Jan. ... (OTC) cough and cold medicines, the Consumer Healthcare,Products Association ... Administration (FDA) decision against the use of oral OTC ...
Cached Medicine News:Health News:OrthoSynetics(TM) Opens Regional Offices in Dallas, Atlanta 2Health News:Battling potential disease outbreaks online 2Health News:Researcher, magnet lab receive $2 million grant to target tuberculosis 2Health News:Relatives who decline organ donations face conflict and guilt 2Health News:Relatives who decline organ donations face conflict and guilt 3Health News:China Nepstar Chain Drugstore Launches Charitable Initiative to Promote Awareness of Low-income Working Women's Health Issues 2Health News:China Nepstar Chain Drugstore Launches Charitable Initiative to Promote Awareness of Low-income Working Women's Health Issues 3Health News:China Nepstar Chain Drugstore Launches Charitable Initiative to Promote Awareness of Low-income Working Women's Health Issues 4Health News:CHPA Lends Support to FDA's Announcement Against Use of Oral, Over-the-Counter Cough and Cold Medicines in Children Under Two 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: